Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Selecting patients for early clinical trials is a challenging process and clinicians lack sufficient tools to predict overall survival (OS). Circulating cell-free DNA (cfDNA) has recently been shown to be a promising prognostic biomarker. The aim of this study was to investigate whether baseline cfDNA measurement could improve the prognostic information of the Royal Marsden Hospital (RMH) score.

METHODS: Solid tumour patients referred for phase I trials were included in the Copenhagen Personalized Oncology (CoPPO) programme. Baseline characteristics were collected prospectively, including the RMH prognostic score, Eastern Cooperative Oncology Group (ECOG) performance status and concentration of cfDNA per millilitre plasma. Cox proportional hazards model was used to assess the prognostic value of baseline variables.

RESULTS: Plasma cfDNA concentration was quantifiable in 302 patients out of a total of 419 included in the study period of 2 years and 5 months. The RMH score was confirmed to be associated with OS. Cell-free DNA was shown to be an independent prognostic marker of OS and improved the risk model, including RMH, performance status and age. Furthermore, both plasma cfDNA concentration and RMH score were associated with treatment allocation (p < 0.00001).

CONCLUSION: Our model based on RMH score, age, ECOG performance status and cfDNA improved prediction of OS and constitutes a clinically valuable tool when selecting patients for early clinical trials. An interactive version of the prognostic model is published on http://bit.ly/phase1survival .

Original languageEnglish
JournalBritish Journal of Cancer
Volume121
Issue number2
Pages (from-to)125-130
Number of pages6
ISSN0007-0920
DOIs
Publication statusPublished - Jul 2019

ID: 58968611